drugset / Trial / NCT06316830

Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose

NCT06316830

Phase 2/3 Recruiting 250 enrolled Rhode Island Hospital Brown University · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment response based on use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (exploratory outcome).

Timeline

Start
2025-01-06
Primary completion
2027-08-01
Completion
2027-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 16 mg
Subject Buprenorphine Other / unclassified 24 mg